Zydus Lifesciences introduces new drug in US markets
According to IQVIA MAT data, Mirabegron extended-release tablets (USP 25mg and 50mg) had yearly sales of USD 2.42 billion in the United States.
Stay updated with breaking news from Punit Patel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
According to IQVIA MAT data, Mirabegron extended-release tablets (USP 25mg and 50mg) had yearly sales of USD 2.42 billion in the United States.
The company has launched Mirabegron extended-release tablets in strength of 25 mg in the US market after having received final approval from the US Food and Drug Administration (USFDA), Zydus Lifesciences said in a regulatory filing.
Zydus Lifesciences Limited announces the launch of Mirabegron Extended-Release Tablets, 25 mg in the US market. The company had earlier received final approval from the United States Food and Drug...
The approval was announced by Zydus Life Sciences Limited in a press release on October 20, 2023.
Punit Patel will be based out of the group's office in Pennington, New Jersey, US, it added. Before joining Zydus, he was the President of Red Oak Sourcing, leading the company's